Generation of BsAb-Specific Anti-idiotypic Antibody

Bispecific antibodies (BsAbs) combine the specificities of two antibodies and simultaneously address different antigens. With this 'two-target' function, BsAb can interfere with multiple surface ligands associated such as cancer, proliferation, or inflammatory processes. While the first BsAb was approved in 2009, BsAbs represent a key component of the next generation of antibody therapy with the current biotherapeutic market dominated by antibody molecules. Hence, the anti-idiotypic antibodies targeted to BsAbs which can bind two different domains are necessary for BsAb research. To date, various commercialized technology platforms are applied for anti-idiotypic antibody creation and production while a few of them are available for dual functional antibodies aimed at BsAb. Therefore, Creative Biolabs has established mature BsAb-binding anti-idiotypic antibody production platforms and launched related products. Moreover, based on our rich experience and skilled groups, we provide commercial and customized one-stop anti-idiotypic antibody production services to support your novel therapeutic molecule research and discovery.

Fig.1 Architecture of common BsAbs formats.¹

Introduction of BsAb

Antibodies with two different antigen-binding sites in one molecule are called bispecific antibodies (BsAbs), which were first reported in the 1960s. Most natural antibodies are multivalent molecules comprising identical antigen-binding sites, hence the BsAbs are generated by biochemical, molecular, or genetic means. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv) antibody and the full-length IgG-like asymmetric antibody. Nowadays, BsAbs are primarily produced by chemical conjugation, quadroma technology based on the somatic fusion of two different hybridoma cell lines, and recombinant DNA technology.

Fig.2 Examples of mechanisms of action of BsAbs.¹

Application of Anti-idiotypic Antibody of BsAb

During the past decades, we have seen a phenomenal evolution of BsAbs for therapeutic applications. Currently, over 70 different BsAb therapeutic antibodies exist, some of which were promoted into the clinical pipeline. However, the lack of detection methods restricts its development and clinical application. While ELISA is a mature and widely used method in protein research, the anti-idiotypic antibodies which can bind both sites of BsAbs are required as primary antibodies in the ELISA detection, which can avoid false-positive and enhance the affinity. Therefore, as a basic tool in BsAb research, bis-functional and specific anti-idiotypic antibodies production became an important step in BsAb therapeutic antibody development.

Fig.3 BsAbs in development and registered in cancer clinical trials. (Suurs, 2019)

With the development of BsAb in the application in clinic treatment, the mature platforms to discover and product novel anti-idiotypic for BsAb is important. If you are interested in our anti-idiotypic antibody production of BsAb services, please feel free to contact us. You can also click here to see more custom anti-idiotypic antibodies production services from Creative Biolabs to meet your specific requirements.

References

Kang, Jingyue, Tonglin Sun, and Yan Zhang. "Immunotherapeutic progress and application of bispecific antibody in cancer." Frontiers in Immunology13 (2022): 1020003.
Suurs, Frans V., et al. "A review of bispecific antibodies and antibody constructs in oncology and clinical challenges." Pharmacology & therapeutics 201 (2019): 103-119.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: